Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.
Dimebon (latrepirdine)Medivation, in collaboration with Pfizer, is currently evaluating dimebon in both Alzheimer’s and Huntington diseases. The Phase 3 CONCERT study, which is currently enrolling patients, is evaluating dimebon in patients already treated with donepezil, the leading Alzheimer’s disease medication worldwide. In addition, we are currently enrolling patients in an international Phase 3 trial known as HORIZON in patients with Huntington disease. For more information about our clinical studies, please contact Medivation at This e-mail address is being protected from spambots. You need JavaScript enabled to view it To learn more about clinical trials, please visit www.clinicaltrials.gov, a service of the U.S. National Institutes of Health.
|
 |
 |
| Medivation © 2010 |